Merck and Moderna's Melanoma Vaccine Phase 3 Trial Succeeds, Paving Way for Regulatory Submission
Nashnova编辑部
Merck and Moderna's personalized cancer vaccine hit its primary endpoint in a Phase 3 trial, keeping post-surgery melanoma patients cancer-free significantly longer than standard therapy — the first-ever Phase 3 success for a therapeutic cancer vaccine, clearing the path for a regulatory submission.
What does this vaccine do, and how well did it work?
Merck (MRK) and Moderna (MRNA) jointly developed a personalized cancer vaccine for melanoma patients.
In the Phase 3 trial, patients had their tumors surgically removed and then received the vaccine; the vaccinated group stayed cancer-free significantly longer than those on standard therapy alone.
This means → the vaccine does not prevent cancer from occurring — it lowers the odds of recurrence and extends disease-free survival after surgery.
Why is this a milestone?
This is the first-ever Phase 3 success for a therapeutic cancer vaccine — every prior candidate in the category failed to reach this stage.
In plain terms = researchers have been chasing cancer vaccines for decades, but none had ever cleared the final, large-scale validation step before approval — until now.
This reflects a turning point: personalized mRNA technology — designing a vaccine matched to each patient's unique tumor mutations — is moving from concept to clinical reality.
What happens next?
With the trial succeeded, Merck and Moderna can now file for marketing authorization with the FDA and other regulators.
This means → if approved, this would become the world's first authorized therapeutic cancer vaccine, opening an entirely new oncology revenue line for both companies.
For investors, the focus shifts to: regulatory timeline, whether the indication can expand beyond melanoma to other cancers, and the manufacturing capacity and pricing of a personalized vaccine.
Content is for reference only, not financial advice.